Phaseline

Targets › RPOB

RPOB: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Infectious disease; next expected readout Mar 2027.

Open in Phaseline: the race on RPOB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Leiden University Medical CenterLevofloxacin
DNA gyrase inhibitor; Topoisomerase IV inhibitor
RPOBPhase 4Prosthetic-joint InfectionMar 2027

Conditions

Prosthetic-joint Infection (1)

Modalities

small molecule (1)

Companies

Leiden University Medical Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.